AlphaQuest LLC Sells 4,660 Shares of DexCom, Inc. $DXCM

AlphaQuest LLC lessened its stake in DexCom, Inc. (NASDAQ:DXCM) by 66.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,385 shares of the medical device company’s stock after selling 4,660 shares during the period. AlphaQuest LLC’s holdings in DexCom were worth $208,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Zions Bancorporation National Association UT bought a new stake in shares of DexCom in the first quarter valued at about $27,000. Anderson Financial Strategies LLC bought a new stake in shares of DexCom in the first quarter valued at about $37,000. Private Trust Co. NA lifted its stake in shares of DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after buying an additional 335 shares during the period. Mather Group LLC. lifted its stake in shares of DexCom by 135.5% in the first quarter. Mather Group LLC. now owns 1,109 shares of the medical device company’s stock valued at $76,000 after buying an additional 638 shares during the period. Finally, Ameritas Advisory Services LLC acquired a new position in DexCom in the second quarter worth about $84,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ DXCM opened at $58.22 on Monday. The firm has a market cap of $22.83 billion, a price-to-earnings ratio of 40.43, a PEG ratio of 1.43 and a beta of 1.47. The company has a 50 day moving average of $70.94 and a 200-day moving average of $78.02. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 1-year low of $56.44 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company’s revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the business posted $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the subject of several recent research reports. The Goldman Sachs Group dropped their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Royal Bank Of Canada dropped their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday. Robert W. Baird set a $82.00 price target on shares of DexCom in a research report on Friday. Finally, Argus initiated coverage on shares of DexCom in a research report on Thursday, August 21st. They issued a “buy” rating and a $100.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $91.65.

Insider Activity

In other news, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 5,383 shares of company stock worth $434,274. Corporate insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.